Phase IV - A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Suvorexant for Insomnia in Parkinson Disease
This study uses a crossover design, which means that it’s divided into two treatment periods in which subjects will receive the drug suvorexant for half of the study and placebo the other half. The study will last for approximately 11-15 weeks.
Who may be eligible to participate?
- Subjects aged 30-80 years old
- Diagnosed with Parkinson’s disease and have insomnia
Subjects will be asked to make five scheduled visits to the study office and undergo three overnight sleep studies, as well as scheduling four-to-six phone calls.
Subjects must have a stable Parkinson’s medication regimen for four weeks prior to visit 1 and remain on a stable regimen for the duration of the study.
Daniel Burdick, MD and Pinky Agarwal, MD, FAAN, Booth Gardner Parkinson’s Care Center